MINDWALK HOLDINGS CORP

HYFTNASDAQ

🏆 #3625 by market capEarnings Sep 10US Equity

$1.38▲ $0.02 (+1.47%)

Market closed · at close

1h—

24h▲ 1.5%

7d▲ 3.8%

14d▲ 4.5%

30d▼ 2.1%

1y▼ 31.0%

🏦Market Cap

$65M

Small Cap

📈Revenue Growth (YoY)

-36.5%

Declining

📊Gross Margin

58.8%

Healthy

💵FCF Margin

5.7%

Moderate

⚖️P/S Ratio

5.7x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $1.37 – $1.39
52-Week Range: —
Volume: $2.53B
Avg Volume: $2.03B
Shares Outstanding: 47.0M
Next Earnings: Sep 7, 2026

Fundamentals Snapshot

Annual Revenue: $15M
Last Q Revenue: $4M
P/E Ratio: —
P/S Ratio: 5.7x
EPS (TTM): —
Dividend Yield: —

Why Investors Own HYFT

✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$15M▲ +32.8% YoY

Gross Margin (TTM)

43.6%▲ +4.5% YoY

Operating Income (TTM)

$3M▲ +32.8% YoY

Free Cash Flow (TTM)

$2M▲ +32.8% YoY

About MINDWALK HOLDINGS CORP

MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.

🦦